LASA
Lasa Supergenerics financials
- Market cap
- ₹33 Cr
- Sector
- Healthcare
What Lasa Supergenerics Limited does
Lasa Supergenerics manufactures Active Pharmaceutical Ingredients using proprietary 'catalyst chemistry', covering the process from basic/advanced intermediates through to finished veterinary and human APIs at its own plants. It sells to multinational pharma companies, the poultry and dairy industry, and small domestic formulators & traders, both in India and via exports to countries such as China, Korea, Bangladesh, Australia and the Middle East. Its intermediates unit backward-integrates supply for its own API units, reducing dependence on outside vendors for key raw materials.
Segments
- Veterinary API
- Human API
- Animal feed ingredients & therapeutic reagents
- Intermediates (captive)
- Manufacturing plants
- 3 GMP-certified units (Unit-1 Mahad, Unit-2 & Unit-3 Khed), Maharashtra
- Total volumetric manufacturing capacity
- ~5,300 TPA (rated capacity 3,100 TPA)
- Product portfolio
- 37 products across Animal API, Human API and Animal Feed Ingredients/Therapeutic Reagents
- Customer base
- 300+ customers across India and international markets
- Proprietary catalyst patents
- 6 patents covering key API products
- Export markets
- China, Korea, Bangladesh, Australia, Turkey, Egypt, Jordan, Middle East
Quarterly results
Q1 FY27: revenue down 93.9%, net profit up 83.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39 | 33 | 39 | 20 | 3 −92% | 2 −93% | -0 −100% | 1 −94% |
| EBITDA | 1 | 0 | 3 | -0 | -4 −606% | -1 −378% | -2 −162% | -1 −178% |
| Net profit | -3 | 5 | -14 | -21 | -6 −93% | -3 −146% | -4 +71% | -4 +83% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −38.8% 1Y
1Y: ₹10.65 on 8 Sept 2025 → ₹6.52. High ₹13.92 (16 Sept 2025), low ₹5.67 (30 Mar 2026).
Financials, as filed
Revenue fell 50.9% a year over 2 years, FY24 to FY26. Operating margin narrowed to -29.3%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹104 Cr | ₹142 Cr | ₹25 Cr |
| Operating profit | ₹2 Cr | ₹6 Cr | ₹-7 Cr |
| Operating margin | 2.1% | 4.4% | -29.3% |
| Interest | ₹2 Cr | ₹3 Cr | ₹0 Cr |
| Depreciation | ₹11 Cr | ₹12 Cr | ₹6 Cr |
| Net profit | ₹-22 Cr | ₹-15 Cr | ₹-34 Cr |
| Net margin | -20.8% | -10.4% | -135.6% |
| Cash from operations | ₹2 Cr | ₹-3 Cr | ₹0 Cr |
| Free cash flow | ₹0 Cr | ₹5 Cr | ₹0 Cr |
| ROCE | -6.0% | -1.0% | -18.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹41 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr |
| Reserves | ₹118 Cr | ₹108 Cr | ₹68 Cr | ₹47 Cr | ₹6 Cr | ₹0 Cr |
| Borrowings | ₹19 Cr | ₹20 Cr | ₹22 Cr | ₹22 Cr | ₹7 Cr | ₹10 Cr |
| Other liabilities | ₹29 Cr | ₹31 Cr | ₹24 Cr | ₹32 Cr | ₹8 Cr | ₹7 Cr |
| Total liabilities | ₹208 Cr | ₹209 Cr | ₹164 Cr | ₹151 Cr | ₹72 Cr | ₹66 Cr |
| Fixed assets | ₹143 Cr | ₹137 Cr | ₹119 Cr | ₹110 Cr | ₹58 Cr | ₹55 Cr |
| Capital work in progress | ₹0 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹65 Cr | ₹67 Cr | ₹40 Cr | ₹39 Cr | ₹13 Cr | ₹11 Cr |
| Total assets | ₹208 Cr | ₹209 Cr | ₹164 Cr | ₹151 Cr | ₹72 Cr | ₹66 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
The ownership split has held steady since Mar 2025. The shareholder count grew 2% to 27,702.
- Promoters
- 53.6%
- Public
- 46.4%
Since Mar 2025
- Promoters 0.00 pp
- FIIs 0.00 pp
- Public 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Jun '23: Promoters 53.6%, Public 46.3%.Sep '23: Promoters 53.6%, Public 46.3%.Dec '23: Promoters 53.6%, FIIs 0.0%, Public 46.3%.Mar '24: Promoters 53.6%, FIIs 0.1%, Public 46.2%.Jun '24: Promoters 53.6%, Public 46.3%.Sep '24: Promoters 53.6%, FIIs 0.0%, Public 46.3%.Dec '24: Promoters 53.6%, Public 46.4%.Mar '25: Promoters 53.6%, Public 46.4%.Jun '25: Promoters 53.6%, FIIs 0.5%, Public 45.9%.Sep '25: Promoters 53.6%, Public 46.4%.Dec '25: Promoters 53.6%, Public 46.3%.Mar '26: Promoters 53.6%, Public 46.4%.
Who is on the register
Named in the Mar 2026 filing
Every holder of Lasa Supergenerics Limited above SEBI's 1% disclosure line, and what changed since Dec 2025.
| Holder | Stake | Change |
|---|---|---|
| Omkar Pravin Herlekar | 53.65% | unchanged |
| Mahendra Girdharilal Wadhwani | 1.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Lasa Supergenerics Limited
Guides on how to read this kind of business and the numbers that matter.